CoChat

Difluorinated-Curcumin (CDF): A Novel Curcumin Analog is a Potent Inhibitor of Colon Cancer Stem-Like Cells

Open access
Kanwar, Shailender Singh, Yu, Yingjie, Nautiyal, Jyoti, Patel, Bhaumik B., Padhye, Subhash, Sarkar, Fazlul H., Majumdar, Adhip P. N. · 2011 · Pharmaceutical Research
Cited by 136

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

ABSTRACTPurposeRecurrence of colon cancer, which affects nearly 50% of patients treated by conventional therapeutics, is thought to be due to re-emergence of chemotherapy-resistant cancer stem/stem-like cells (CSCs). Therefore, development of therapeutic strategies for targeted elimination of CSCs would be a novel strategy. The current study examines whether diflourinated-curcumin (CDF), a novel analog of the dietary ingredient of curcumin, in combination with 5-fluorouracil and oxaliplatin (5-FU + Ox), the mainstay of colon cancer chemotherapeutic, would be effective in eliminating colon CSCs.MethodsMultiple methodologies that include real-time RT-PCR, Western blot, MTT assay, caspase-3 activity, colonosphere formation, Hoechst-33342 dye exclusion and NF-κB-ELISA were used.ResultsWe observed that CDF together with 5-FU + Ox were more potent than curcumin in reducing CD44 and CD166 in chemo-resistant colon cancer cells, accompanied by inhibition of growth, induction of apoptosis and disintegration of colonospheres. These changes were associated with down-regulation of the membrane transporter ABCG2 and attenuation of EGFR, IGF-1R, and NF-κB signaling consistent with inactivation of β-catenin, COX-2, c-Myc and Bcl-xL and activation of the pro-apoptotic Bax.ConclusionsOur results suggest that CDF together with the conventional chemotherapeutics could be an effective treatment strategy for preventing the emergence of chemo-resistant colon cancer cells by eliminating CSCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11095-010-0336-y

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Cancer statistics, 2009

    Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709

  • Bioavailability of curcumin: Problems and promises

    Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543 · cited 1×

    “excreted in the feces (14) and also undergoes rapid inactivation due to glucuronidation (15), several strategies”
  • Tumour stem cells and drug resistance

    Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 2×

    “It has been well established that ABCG2 is responsible for protecting cells against xenobiotics or endogenous catabolites that may be toxic under unfavorable hypoxic conditions by active efflux activity, and such intrinsicallyresistant stem cells are understood to contribute towards resistance to chemotherapy (2,29).”

Show all 3 references

Cited by

See all 136

Metadata

Authors
Kanwar, S. S., Yu, Y., Nautiyal, J., Patel, B. B., Padhye, S., Sarkar, F. H., & Majumdar, A. P. N.
Venue
Pharmaceutical Research
Published
2010-12-14
Volume
28
Issue
4
Pages
827-838
ISSN
  • 0724-8741 (ISSN-L)
  • 1573-904X
OpenAlex
W2167564369
Cited by
136
References
3
FWCI
5.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Difluorinated-Curcumin (CDF): A Novel Curcumin Analog is a Potent Inhibitor of Colon Cancer Stem-Like Cells. https://app.cochat.ai/papers/10.1007/s11095-010-0336-y
The paper
Kanwar, S. S., Yu, Y., Nautiyal, J., Patel, B. B., Padhye, S., Sarkar, F. H., & Majumdar, A. P. N. (2011). Difluorinated-Curcumin (CDF): A Novel Curcumin Analog is a Potent Inhibitor of Colon Cancer Stem-Like Cells. Pharmaceutical Research. https://doi.org/10.1007/s11095-010-0336-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.